A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

NCT07319845 | Recruiting Phase 2

• 2 other identifiers: TAK-226-2001jRCT2031250603
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 20

Brief Summary

The main aim of the study is to evaluate how TAK-226 improves symptoms of transfusion-dependent anemia in Japanese patients with lower-risk myelodysplastic syndromes. The study consists of Screening Period (up to 6 weeks), Treatment Period, Safety Follow-Up Period (8 weeks), and Long-Term Follow-Up Period (5 years from the first dose of the study drug or 3 years after the last dose, whichever is longer). Participants of this study will be administered TAK-226 during Treatment Period. Subsequently, the participants will be monitored for side effects related to the study treatment during Safety Follow-Up Period and Long-Term Follow-Up Period. The approximate duration of participation for a participant is up to approximately 6 years. During the study period, participants will visit the study clinic/hospital multiple times as per the study schedule. During Treatment Period, the participants will come to the clinic/hospital approximately every two to four weeks.

Conditions

Myelodysplastic Syndromes

Keywords

Drug Therapy

Outcome Measures

Primary Outcomes (2)

• Transfusion dependent (TD) cohort: Percentage of Participants Achieving Transfusion Independence (TI) for Greater Than or Equal to (>=) 8 Weeks from Baseline through Week 24

  Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.

  Baseline, Up to Week 24

• Non-transfusion dependent (NTD) cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 grams per deciliter (g/dL) for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks Period

  Baseline, Up to Week 24

Secondary Outcomes (63)

• TD cohort: Percentage of Participants Achieving TI for >=24 Weeks from Baseline through Week 48

  Baseline, Up to Week 48

• TD cohort: Percentage of Participants with High Transfusion Burden (HTB) Achieving TI for >=8 Weeks from Baseline through Week 24

  Baseline, Up to Week 24

• TD cohort: Percentage of Participants Achieving Mean Hemoglobin (Hgb) Increase of >=1.5 g/dL for >=8 Weeks from Baseline through Week 24

  Baseline, Up to Week 24

• TD cohort: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Event (SAEs)

  Up to approximately 6 years

• TD cohort: Serum Concentration of TAK-226

  Baseline, and multiple time points up to the end of Treatment Period (approximately 12 months)

Study Arms (1)

TAK-226

EXPERIMENTAL

Participants will receive the study drug, TAK-226, administered subcutaneously every four weeks (Q4W) for approximately one year during Treatment Period.

Drug: TAK-226

Interventions

TAK-226 DRUG

TAK-226 subcutaneous injection

Also known as: Elritercept, KER-050

TAK-226

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants or their legally authorized representative must be willing and able to sign the ICF and to adhere to the protocol requirements.
• Japanese adult male or female participant \>=18 years of age at the time of signing informed consent.
• Diagnosis of MDS with or without ring sideroblasts (RS) (as determined in an evaluable bone marrow aspirate collected at Screening to confirm diagnosis) according to WHO 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low-, low-, or intermediate-risk MDS.
• Note: Due to expected impacts of transfusion, hemoglobin (Hgb) values from blood samples collected within 14 days following a RBC transfusion and platelet count obtained within 7 days following a platelet transfusion cannot be used to evaluate IPSS-R for eligibility.
• TD\[YY1.1\] cohort: Transfusion dependence assessed in the 16 weeks immediately preceding enrollment in two 8-week blocks classified as either:
• Low-transfusion burden (LTB), defined as 4 to 7 RBC units per 16 weeks; or
• HTB\[YY2.1\], defined as \>=8 RBC units per 16 weeks; and
• For all participants: i. Only transfusion events for a pretransfusion Hgb \<10 g/dL are counted toward eligibility; ii. At least 1 transfusion event in each 8-week block and a minimum of 2 transfusion events separated by \>=7 days within the 16-week period immediately preceding enrollment; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16 week period immediately preceding enrollment.
• Note: Only transfusions for the disease under study will be counted towards classification for LTB or HTB participants. Transfusions for intercurrent diseases (bleeding, surgical procedure, infection, etc.) are not considered.
• NTD\[YY3.1\] cohort: NTD, defined as 0 to 1 RBC units per 8 weeks immediately preceding enrollment.
• Note: RBC transfusions administered when Hgb levels were \<9.0 g/dL are counted for eligibility. RBC transfusions administered for other than MDS-related anemia (bleeding, surgical procedure, infection, etc.) will not be counted as a required transfusion for the purpose of meeting eligibility criteria.
• TD cohort: Refractory or intolerant to prior erythropoiesis-stimulating agent (ESA) treatment (discontinued \>=4 weeks before enrollment), or unlikely to respond to ESA treatment, defined as follows:
• a. Refractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (eg, with granulocyte colony-stimulating factor \[G-CSF\]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) \>=40,000 IU/week for \>=8 doses or equivalent; or ii. Darbepoetin alpha \>=500 mcrg every 3 weeks for \>=4 doses or equivalent. b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.
• c. Unlikely to respond to ESA treatment: low chance of response to ESA based on an endogenous serum EPO level \>200 U/L.
• Note: Due to expected impacts of transfusion on EPO levels, blood samples collected within the 14 days following an RBC transfusion or within 7 days following a platelet transfusion cannot be used to evaluate serum EPO level for eligibility.

You may not qualify if:

• Medical History
• Del(5q) MDS or therapy-related (secondary) MDS.
• Anemia due to any other known cause (eg, thalassemia, hemolytic anemia, bleeding events, or deficiency of iron, B12, and/or folate).
• Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks in TD cohort or 8 weeks in NTD cohort before enrollment.
• Clinically significant cardiovascular disease defined as:
• New York Heart Association heart disease class III or IV;
• Fridericia corrected QT (QTcF) interval \>500 milliseconds during Screening;
• Presence of uncontrolled hypertension defined as mean systolic blood pressure \>=160 mm Hg or diastolic blood pressure \>=100 mm Hg during Screening; or
• Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before Screening.
• Known ejection fraction \<35%, confirmed by a local echocardiogram performed during Screening, or a previously performed echocardiogram if collected within 6 months before Screening.
• Stroke, deep vein thrombosis, or pulmonary embolism within 6 months before Screening.
• Any known history of acute myeloid leukemia (AML).
• Prior history of malignancies, other than MDS, unless the participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for \>=5 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:
• Basal or squamous cell carcinoma of the skin;
• Carcinoma in situ of the cervix;

Sponsors & Collaborators

• Takeda: lead

Study Sites (20)

Tokyo Metropolitan Komagome Hospital

Tokyo, Bunkyo-ku, Japan

NOT YET RECRUITING

University of Fukui Hospital

Fukui, Eiheiji, Japan

NOT YET RECRUITING

Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital

Hiroshima, Fukuyama, Japan

NOT YET RECRUITING

Tokai University Hospital

Kanagawa, Isehara, Japan

NOT YET RECRUITING

JCHO Kyushu Hospital

Fukuoka, Kitakyushu, Japan

NOT YET RECRUITING

Kobe City Hospital Organization Kobe City Medical Center General Hospital

Hyōgo, Kobe, Japan

NOT YET RECRUITING

Yamanashi Prefectural Central Hospital

Yamanashi, Kofu, Japan

NOT YET RECRUITING

Matsuyama Red Cross Hospital

Ehime, Matsuyama, Japan

NOT YET RECRUITING

Dokkyo Medical University Hospital

Tochigi, Mibu, Japan

NOT YET RECRUITING

National Hospital Organization Nagoya Medical Center

Aichi, Nagoya, Japan

NOT YET RECRUITING

Japanese Red Cross Narita Hospital

Chiba, Narita, Japan

NOT YET RECRUITING

Kitasato University Hospital

Kanagawa, Sagamihara, Japan

NOT YET RECRUITING

Kindai University Hospital

Osaka, Sakai, Japan

NOT YET RECRUITING

Hokuyukai Sapporo Hokuyu Hospital

Hokkaido, Sapporo, Japan

RECRUITING

National University Corporation Tohoku University Tohoku University Hospital

Miyagi, Sendai, Japan

NOT YET RECRUITING

NTT Medical Center Tokyo

Tokyo, Shinagawa-ku, Japan

RECRUITING

National Hospital Organization Kyushu Medical Center

Fukuoka, Japan

NOT YET RECRUITING

Gifu Municipal Hospital

Gifu, Japan

NOT YET RECRUITING

Japanese Red Cross Nagasaki Genbaku Hospital

Nagasaki, Japan

NOT YET RECRUITING

Okayama City General Medical Center Okayama City Hospital

Okayama, Japan

NOT YET RECRUITING

Related Links

• Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.
• Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language.

MeSH Terms

Conditions

Myelodysplastic Syndromes

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Central Study Contacts

Takeda Contact

CONTACT

+1-877-825-3327; medinfoUS@takeda.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 22, 2025
• First Posted: January 6, 2026
• Study Start: April 22, 2026
• Primary Completion (Estimated): June 26, 2028
• Study Completion (Estimated): January 10, 2033
• Last Updated: July 16, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Locations

JP (20)